Thermo Fisher Scientific's One Lambda Brand Signs Exclusive Licensing Agreement with Transcriptome Sciences Inc. for access to Molecular Microscope Diagnostic System
Press Release
CANOGA PARK, Calif., May 16, 2017 /PRNewswire/ -- One Lambda, a Thermo Fisher Scientific brand, announced today that it has signed an exclusive licensing agreement with Transcriptome Sciences Inc. (TSI) of Edmonton, Canada for its new microarray biopsy service, the Molecular Microscope™ Diagnostic System (MMDx).
"The MMDx is a truly innovative way of assessing transplant rejection. There is a lot of contention with the results from the current technology."Dr. Jon Kobashigawa | Cardiologist and Director, Heart Transplant Program • Cedars-Sinai Hospital, Los Angeles
Developed by TSI, MMDx is a central diagnostic system that uses a "MyGeneChip™ Custom Microarray from Thermo Fisher Scientific to measure transcript levels in biopsies, apply algorithms and compare algorithm results to a set of reference biopsies. The system was developed for kidney transplant biopsies by Dr. Phil Halloran in the Alberta Transplant Applied Genomics Centre at the University of Alberta in Edmonton, Canada, and its company, Transcriptome Sciences Inc. (TSI). The Molecular Microscope system has been adapted to read heart transplant biopsies and is now being adapted to read lung and liver transplant biopsies. The mission is to change the care of patients in organ transplantation with this new central diagnostic system.
Read full Press Release
